» Articles » PMID: 27212656

A Cross-national Analysis of the Effects of Methadone Maintenance and Needle and Syringe Program Implementation on Incidence Rates of HIV in Europe from 1995 to 2011

Overview
Publisher Elsevier
Date 2016 May 24
PMID 27212656
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Although many studies have found an association between harm reduction interventions and reductions in incidence rates of Human Immunodeficiency Virus (HIV) infection, scant research explores the effects of harm reduction cross-nationally. This study used a year- and country-level fixed effects model to estimate the potential effects of needle-and-syringe programs (NSPs) and methadone maintenance therapy (MMT) on incidence rates of HIV in the general population and among people who inject drugs (PWID), in a sample of 28 European nations. After adjusting for Gross Domestic Product (GDP) and total expenditures on healthcare, we identified significant associations between years of MMT and NSP implementation and lower incidence rates of HIV among PWID and the general population. In addition to years of implementation of NSP and MMT, the greater proportion of GDP spent on healthcare was associated with a decrease in logged incidence rates of HIV. The findings of this study suggest that MMT and NSP may reduce incidence rates of HIV among PWID cross-nationally. The current study opens a new avenue of exploration, which allows for a focus on countrywide policies and economic drivers of the epidemic. Moreover, it highlights the immense importance of the adoption of harm reduction programs as empirically-based health policy as well as the direct benefits that are accrued from public spending on healthcare on incidence rates of HIV within the general population and among subpopulations of PWID.

Citing Articles

Could 30 years of political controversy on needle exchange programmes in Sweden contribute to scaling-up harm reduction services in the world?.

Karlsson N, Berglund T, Ekstrom A, Hammarberg A, Tammi T Nordisk Alkohol Nark. 2022; 38(1):66-88.

PMID: 35309093 PMC: 8899060. DOI: 10.1177/1455072520965013.


Dealing with low access to harm reduction: a qualitative study of the strategies and risk environments of people who use drugs in a small Swedish city.

Holeksa J Harm Reduct J. 2022; 19(1):23.

PMID: 35246162 PMC: 8894830. DOI: 10.1186/s12954-022-00602-y.


A cross-national analysis of the association between years of implementation of opioid substitution treatments and drug-related deaths in Europe from 1995 to 2013.

Marotta P, McCullagh C Eur J Epidemiol. 2017; 33(7):679-688.

PMID: 29234968 PMC: 5997507. DOI: 10.1007/s10654-017-0342-z.

References
1.
Riley E, Safaeian M, Strathdee S, Marx M, Huettner S, Beilenson P . Comparing new participants of a mobile versus a pharmacy-based needle exchange program. J Acquir Immune Defic Syndr. 2000; 24(1):57-61. DOI: 10.1097/00126334-200005010-00010. View

2.
De Cock K, El-Sadr W, Ghebreyesus T . Game changers: why did the scale-up of HIV treatment work despite weak health systems?. J Acquir Immune Defic Syndr. 2011; 57 Suppl 2:S61-3. DOI: 10.1097/QAI.0b013e3182217f00. View

3.
Khoshnood K, Blankenship K, Pollack H, Roan C, Altice F . Syringe source, use, and discard among injection-drug users in New Haven, Connecticut. AIDS Public Policy J. 2002; 15(3-4):88-94. View

4.
van den Berg C, Smit C, van Brussel G, Coutinho R, Prins M . Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007; 102(9):1454-62. PMC: 2040242. DOI: 10.1111/j.1360-0443.2007.01912.x. View

5.
Rhoades H, Creson D, Elk R, Schmitz J, Grabowski J . Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health. 1998; 88(1):34-9. PMC: 1508390. DOI: 10.2105/ajph.88.1.34. View